 WALTHAM, Mass., Oct. 12, 2022 GLOBE NEWSWIRE -- Invivyd, Nasdaq: IVVD, formerly Adagio Therapeutics Nasdaq: ADGI, a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022. The posters will share findings from several studies surrounding adintrevimab, including data from the Phase 1 and Phase 23 clinical trials. 